"Interventional Glaucoma (IG) is a mindset shift utilizing early predictive diagnostics,
active patient monitoring, and early procedural-based intervention over a patient's
lifetime. The need to safely intervene earlier is designed to mitigate disease
progression, reduce the need for more invasive procedures, and enhance patient
quality of life. Working together with the glaucoma community, we can drive this
paradigm shift and advance glaucoma patient care."
- Ike Ahmed, MD; Tom Samuelson, MD; John Berdahl, MD*
We go fi rst.
Glaukos pioneered the global
MIGS marketplace and is
leading the emergence of the
IG paradigm shift. Our global IG
teams are dedicated to delivering
leading technologies, services,
and support to enable this
evolution for years to come.
Contact your local Glaukos
representative to learn more
about our IG initiative.
FOR THE LIFELONG PATIENT JOURNEY
IG: THE COMING
EVOLUTION
* Paid Glaukos consultants.
©2024 Glaukos Corporation. All rights reserved. Glaukos is a
registered trademark of Glaukos Corporation. PM-US-2315
IG-focused personnel supporting you,
your practice, and your patients
MIGS and procedural pharmaceutical
technologies that span the disease
continuum (OHT-Refractory)
Industry-leading clinical evidence with
long-term follow-up
Educational programs and support
designed to advance IG
Unparalleled Research and
Development pipeline of
next-generation innovation
